Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.7740
Nov 06 • 4:00 AM ET Dollar change+0.0489 Percentage change(6.74%)
Index
-
Market Cap
4.69M
Enterprise Value
-1.63M
Income
-12.27M
Sales
0.00M
Book/sh
1.21
Cash/sh
1.11
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
Jun 16, 2023
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.64
P/C
0.70
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.86
Current Ratio
4.86
Debt/Eq
0.06
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-13.06
EPS next Y
-0.64
EPS next Q
-0.25
EPS this Y
90.89%
EPS next Y
68.78%
EPS next 5Y
69.96%
EPS past 3/5Y
78.38% 67.17%
Sales past 3/5Y
- -
EPS Y/Y TTM
78.16%
Sales Y/Y TTM
-100.00%
EPS Q/Q
85.32%
Sales Q/Q
-
Insider Own
-
Insider Trans
-
Inst Own
32.13%
Inst Trans
39.48%
ROA
-190.69%
ROE
-256.67%
ROIC
-166.18%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-28.31%
SMA50
-45.61%
SMA200
-58.50%
Trades
Shs Outstand
6.06M
Shs Float
5.65M
52W High
4.56 -83.03%
52W Low
0.52 49.42%
Volatility
17.33% 25.94%
ATR (14)
0.21
RSI (14)
38.84
Beta
-0.94
Rel Volume
0.03
Avg Volume
2.98M
Volume
4,936
Perf Week
0.62%
Perf Month
-41.36%
Perf Quarter
-44.71%
Perf Half Y
-66.97%
Perf YTD
-70.77%
Perf Year
-82.28%
Perf 3Y
-99.97%
Perf 5Y
-
Perf 10Y
-
Prev Close
0.73
Price
0.77
Change %
6.74%
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.
PresidentMr. Francisco D. Salva
Ph.D.Dr. Travis M. Whitfill M.P.H.
CFO & TreasurerMr. Norman Staskey